Hanall Biopharma Co Ltd
KRX:009420
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (46.9), the stock would be worth ₩12 308.95 (74% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 180.7 | ₩47 400 |
0%
|
| 3-Year Average | 46.9 | ₩12 308.95 |
-74%
|
| Industry Average | 23.2 | ₩6 096.62 |
-87%
|
| Country Average | 15.1 | ₩3 951.77 |
-92%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
Hanall Biopharma Co Ltd
KRX:009420
|
2.4T KRW | 180.7 | -433 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.1 |
| Median | 15.1 |
| 70th Percentile | 28.4 |
| Max | 21 200 |
Other Multiples
Hanall Biopharma Co Ltd
Glance View
Hanall Biopharma Co., Ltd., a Seoul-based pharmaceutical entity, has been navigating the competitive seas of the global health industry since 1973. Driven by a mission to address unmet medical needs, the company has positioned itself at the forefront of innovative drug development and biosimilars. Hanall's spotlight in recent years has been on its dedication to improving the lives of patients suffering from autoimmune and rare diseases. By focusing on cutting-edge solutions, the firm has garnered attention through its proprietary products and partnerships, such as its notable alliance with Harbour BioMed. This partnership has been pivotal in propelling their flagship drug candidates through the complex corridors of clinical trials and regulatory approvals. Central to Hanall Biopharma's business model is a dual strategy: developing novel therapeutics and capitalizing on biosimilar drugs. The company invests significantly in research and development, orchestrating a pipeline that balances groundbreaking therapies with the more predictable revenue streams of biosimilars. These biosimilars, essentially comparable versions of existing biologic drugs, allow Hanall to leverage lower development costs while addressing market demands for more affordable healthcare solutions. With revenues flowing from successful collaborations and sales of active pharmaceuticals, Hanall continues to chart a course through the diverse challenges of biopharmaceutical innovation and market competition.
